Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6;40(25):2878–2888. doi: 10.1200/JCO.22.00839

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Response parameters according to the treatment arm: (A) ORR and disease control rate and (B) early tumor shrinkage. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. CR, complete response; DCR, disease control rate; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, and irinotecan; NE, not evaluable; OR, odds ratio; ORR, objective response rate; PD, progression disease; PR, partial response; SD, stable disease.